HHS Peptide Compounding Discretion Expands Risk Without Evidence or Precedent

HHS Policy on Unapproved Peptides Sparks Safety and Development Concerns

The Department of Health and Human Services (HHS) has issued an interim enforcement discretion policy allowing compounding pharmacies to produce six unapproved peptide products, despite scientific concerns raised by FDA reviewers. This move, championed by Health Secretary Robert F. Kennedy Jr., is criticized for potentially endangering patients by expanding access to experimental peptides without adequate clinical evidence. The author argues that this policy could undermine confidence in legitimate compounding, weaken incentives for rigorous drug development, and divert investment away from well-studied treatment options, ultimately harming patients and the pharmaceutical industry.

• HHS released an interim enforcement discretion policy permitting state-licensed pharmacies and physicians to compound six unapproved peptide products. This decision followed a recommendation from the FDA’s Pharmacy Compounding Advisory Committee (PCAC) to include these peptides on a list for traditional compounding, despite the FDA's own scientific reviewers recommending against all seven peptides due to substantive concerns regarding effectiveness, identity, purity, and potential immune reactions.
• FDA scientific reviewers identified significant evidence gaps for specific peptides. For BPC-157, they found insufficient evidence for its effectiveness in ulcerative colitis. For KPV, no human clinical data supported its proposed uses. Broader concerns included the substances' identity and purity, and their potential to trigger adverse immune reactions, which HHS's cited additional data has not adequately addressed according to the author.
• The policy risks creating a competing route for experimental peptides, potentially weakening incentives for pharmaceutical companies to invest in rigorous clinical research and FDA approval pathways. This could lead to fewer well-studied treatment options, persistent uncertainty for patients, and challenges in recruiting for clinical trials. The author emphasizes that while compounding has a legitimate role, expanding commercial access to unapproved substances without robust evidence jeopardizes patient safety and the integrity of drug development.

Where BPC-157 and KPV Are Being Clinically Explored

BPC-157 and KPV have been explored beyond their lead gastrointestinal programs across inflammatory, wound healing and pain settings, with human experience limited to small pilot studies for BPC-157 and preclinical colitis models for KPV.
Preclinical work further extends to cutaneous wounds, ligament healing and colitis-associated cancer models using targeted delivery systems.

Unpacking the Safety Data for BPC-157 and KPV

Published safety and tolerability data for BPC-157 are limited to fewer than 30 subjects across three uncontrolled pilot studies, none of which employed standardized pharmaceutical preparations, with no completed Phase II clinical trial. KPV safety data are limited to in vitro cytocompatibility and cell viability assessments in intestinal and colitis model systems, with no human tolerability data reported.

• BPC-157 overall clinical tolerability: In available human trials (non-cardiac) to date, BPC-157 has not demonstrated adverse effects, with no approved formulation, no validated dosing regimen, and no pharmaceutical-grade formulation developed or validated.

• Intravesical BPC-157 in interstitial cystitis: Twelve women between the ages of 39 and 76 years with a mean age of 58.3 years received a total of 10 mg around the area of inflammation of the bladder during a single procedure, with no one dropping out of the study and no adverse events reported.

• Intravenous BPC-157 pilot: Two patients, a 58-year-old Asian male and a 68-year-old Caucasian female, received 10 mg of BPC-157 in 250 cc of normal saline infused over one hour on day 1 and 20 mg of BPC-157 in 250 cc of normal saline infused over one hour on day 2, with no measurable effects on the tested biomarkers of the heart, liver, kidneys, thyroid, or blood glucose levels, tolerated with no side effects reported.

• Preclinical toxicology signal for BPC-157: LD1 not achieved in toxicology studies, described as a prominent cytoprotection mediator with well-matched cytoprotective-antiarrhythmic effects.

• KPV in vitro biocompatibility: HA-KPV-NPs appear to be nontoxic and biocompatible with intestinal cells, NPs (400 nm) did not affect cell viability or barrier functions, and DCM-KPV showed negligible cytotoxicity and high cytocompatibility in living cells.